Neumora Therapeutics Croissance future
Future contrôle des critères 0/6
Neumora Therapeutics devrait augmenter ses bénéfices et son chiffre d'affaires de 11.8% et de 79.9% par an respectivement. Le BPA devrait croître de de 23.9% par an. Le rendement des capitaux propres devrait être -59.2% dans 3 ans.
Informations clés
11.8%
Taux de croissance des bénéfices
23.92%
Taux de croissance du BPA
| Pharmaceuticals croissance des bénéfices | 18.7% |
| Taux de croissance des recettes | 79.9% |
| Rendement futur des capitaux propres | -59.16% |
| Couverture par les analystes | Good |
| Dernière mise à jour | 19 Aug 2026 |
Mises à jour récentes de la croissance future
Recent updates
NMRA: Early Neuroscience Pipeline Will Become Central Driver After Trial Setback
Analysts have cut their average price target for Neumora Therapeutics from about $8.91 to roughly $6.53, reflecting the removal of navacaprant from their models after the KOASTAL-2 and KOASTAL-3 trial setbacks, partially offset by interest in the remaining pipeline and expected cost savings. Analyst Commentary Recent Street research on Neumora Therapeutics centers on the decision to discontinue navacaprant after the KOASTAL-2 and KOASTAL-3 outcomes and how that change affects valuation, cost structure, and focus on the earlier stage pipeline.
NMRA: Early Pipeline And Cost Cuts Will Drive Future Rebound Potential
Neumora Therapeutics' analyst price targets have been cut sharply, with several firms lowering their views into a $4 to $7 range after removing navacaprant from their models following the KOASTAL-2 and -3 Phase 3 failures and incorporating cost savings from a 35% workforce reduction, alongside continued interest in the remaining early-stage pipeline. Analyst Commentary Recent research on Neumora Therapeutics reflects a reset in expectations after the KOASTAL-2 and -3 outcomes, with price targets now clustered in the mid-single digits and coverage largely maintained.Multiple Late Stage Brain Disease Programs Will Drive Long Term Upside Potential
Catalysts About Neumora Therapeutics Neumora Therapeutics develops brain penetrant medicines targeting novel mechanisms for psychiatric, neurologic and metabolic diseases. What are the underlying business or industry changes driving this perspective?CNS And Obesity Pipeline Will Create Long Term Value As Late Stage Data Emerges
Catalysts About Neumora Therapeutics Neumora Therapeutics focuses on developing brain penetrant medicines for neuropsychiatric, neurodegenerative, and metabolic diseases. What are the underlying business or industry changes driving this perspective?Neumora Therapeutics: Downgrading After Navacaprant Development Setback
Summary Neumora Therapeutics is downgraded from 'Strong Buy' to 'Hold' following KOASTAL-1's failure in the MDD primary endpoint. KOASTAL-2 and KOASTAL-3 studies for navacaprant in MDD have increased enrollment; topline data is expected in Q2 2026, but success remains uncertain. NMRA-511 showed a promising signal in phase 1b for Alzheimer's Disease agitation, with an enhanced effect in patients with elevated anxiety. Phase 2 study initiation for NMRA-511 in AD agitation is not expected until Q1 2027, making near-term value realization unlikely despite large unmet market need. Read the full article on Seeking AlphaNeumora Therapeutics: Tanking On Disastrous MDD Data, Bounce Back Unlikely
Summary Neumora Therapeutics' lead candidate, navacaprant, failed to meet primary and secondary endpoints in its Phase 3 KOASTAL-1 study for major depressive disorder, causing an 80% stock drop yesterday. Despite significant funding and a “promising” Phase 2 study, concerns about endpoint changes and lack of peer-reviewed data undermine confidence in navacaprant's efficacy. With two more Phase 3 studies pending, the market may have overreacted, but the likelihood of a turnaround remains slim given current evidence. Neumora's other assets and cash reserves offer limited near-term revenue prospects, making a contrarian bet on navacaprant risky and ill-advised. Read the full article on Seeking AlphaNeumora: Koastal-1 Readout For MDD Treatment Is First Study On Deck
Summary Neumora Therapeutics is set to release data from the phase 3 KOASTAL-1 study using Navacaprant for the treatment of patients with MDD by the end of 2024; other data in 2025. Navacaprant showed significant efficacy in a phase 2 study for MDD and is also being tested for bipolar depression, with phase 2 data expected in late 2025. Neumora has $341.3 million in cash, enough to fund operations until mid-2026, minimizing near-term dilution risk unless management opts otherwise. Key NMRA risks include the potential failure of KOASTAL-1 to meet primary endpoints and uncertainty in Navacaprant's efficacy for bipolar depression and NMRA-511 for Alzheimer's agitation. Read the full article on Seeking AlphaNeumora Therapeutics: A Story Of A Class II Biotech
Summary Neumora Therapeutics' lead asset, Navacaprant, shows weak efficacy in phase 2 trial, casting doubt on its success in upcoming phase 3 trials. The company's AI-driven precision medicine claims have not materialized in clinical trial designs, undermining their differentiation strategy. Valuation models suggest Neumora's stock is overvalued, with a fair valuation significantly lower than the current market price. Read the full article on Seeking AlphaWe're Hopeful That Neumora Therapeutics (NASDAQ:NMRA) Will Use Its Cash Wisely
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Neumora: Phase 3 MDD Readout In H2-24 Could Get Ball Rolling
Summary Results from the phase 3 KOASTAL-1 study, using Navacaprant for the treatment of patients with Major Depressive Disorder, expected in the 2nd half of 2024. The global Major Depressive Disorder [MDD] treatment market is estimated to reach $14.96 billion by 2032. Company hopes to differentiate itself against other MDD drugs in that Navacaprant has a novel MOA, no side effects seen in approved drugs and treat patients not yet helped. Navacaprant is versatile in that it is believed it could also be used to treat patients with bipolar depression; initiation of phase 2 bipolar depression study using this drug expected in the 1st half of 2024. Read the full article on Seeking AlphaPrévisions de croissance des bénéfices et des revenus
| Date | Recettes | Les revenus | Flux de trésorerie disponible | Cash from Op | Moy. Nombre d'analystes |
|---|---|---|---|---|---|
| 12/31/2028 | 8 | -178 | -162 | -154 | 8 |
| 12/31/2027 | N/A | -156 | -142 | -142 | 9 |
| 12/31/2026 | N/A | -169 | -151 | -147 | 9 |
| 6/30/2026 | N/A | -213 | -181 | -181 | N/A |
| 3/31/2026 | N/A | -222 | -193 | -193 | N/A |
| 12/31/2025 | N/A | -237 | -206 | -206 | N/A |
| 9/30/2025 | N/A | -236 | -209 | -209 | N/A |
| 6/30/2025 | N/A | -252 | -196 | -196 | N/A |
| 3/31/2025 | N/A | -258 | -199 | -199 | N/A |
| 12/31/2024 | N/A | -244 | -184 | -183 | N/A |
| 9/30/2024 | N/A | -294 | -189 | -184 | N/A |
| 6/30/2024 | N/A | -274 | -204 | -198 | N/A |
| 3/31/2024 | N/A | -254 | -179 | -173 | N/A |
| 12/31/2023 | N/A | -236 | -168 | -163 | N/A |
| 9/30/2023 | N/A | -155 | -142 | -142 | N/A |
| 6/30/2023 | N/A | -132 | -120 | -120 | N/A |
| 3/31/2023 | N/A | -123 | -116 | -116 | N/A |
| 12/31/2022 | N/A | -131 | -128 | -115 | N/A |
| 9/30/2022 | N/A | -130 | -128 | -114 | N/A |
| 6/30/2022 | N/A | -278 | -119 | -105 | N/A |
| 3/31/2022 | N/A | -265 | -106 | -92 | N/A |
| 12/31/2021 | N/A | -237 | -76 | -75 | N/A |
| 9/30/2021 | N/A | -230 | -65 | -63 | N/A |
| 12/31/2020 | N/A | -99 | -28 | -27 | N/A |
Prévisions de croissance des analystes
Taux de revenus par rapport au taux d'épargne: NMRA devrait rester non rentable au cours des 3 prochaines années.
Bénéfices vs marché: NMRA devrait rester non rentable au cours des 3 prochaines années.
Croissance élevée des bénéfices: NMRA devrait rester non rentable au cours des 3 prochaines années.
Chiffre d'affaires vs marché: NMRA ne devrait pas générer de revenus l'année prochaine.
Croissance élevée des revenus: NMRA ne devrait pas générer de revenus l'année prochaine.
Prévisions de croissance du bénéfice par action
Rendement futur des capitaux propres
ROE futur: NMRA devrait être non rentable dans 3 ans.
Découvrir les entreprises en croissance
Analyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2026/09/11 16:17 |
| Cours de l'action en fin de journée | 2026/09/11 00:00 |
| Les revenus | 2026/06/30 |
| Revenus annuels | 2025/12/31 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github ; nous proposons également des guides sur la façon d’utiliser nos rapports et des tutoriels sur YouTube.
Découvrez l' qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
Neumora Therapeutics, Inc. est couverte par 10 analystes. 9 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| Yatin Suneja | Guggenheim Securities, LLC |
| Douglas Tsao | H.C. Wainwright & Co. |
| Tessa Romero | J.P. Morgan |